<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article183</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/CAPE_COD" style="display:block; margin-bottom:10px;">CAPE COD Original</a></li>
<h2><strong>CAPE COD</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>

    "Hydrocortisone in Severe Community-Acquired Pneumonia".<br/>
<br/>
The New England Journal of Medicine. 2023. <br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
Does the administration of hydrocortisone reduce 28-day mortality in patients with severe community-acquired pneumonia being treated in the ICU?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
In patients with severe community-acquired pneumonia being treated in the ICU, the administration of hydrocortisone resulted in lower 28-day mortality compared with placebo.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/><br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/>
The results of this study could influence future guidelines on the therapy for severe community-acquired pneumonia in the ICU.<br/>
<br/>
<h2><strong>Design</strong></h2><br/>
Double-blind, randomized, controlled superiority trial.<br/>
<br/>
<h2><strong>Population</strong></h2><br/>
795 adults admitted to the ICU for severe community-acquired pneumonia.<br/>
<br/>
Inclusion Criteria<br/>
- Adults â‰¥18 years<br/>
- Severe community-acquired pneumonia requiring ICU admission<br/>
- Presence of specific severity criteria for pneumonia<br/>
<br/>
Exclusion Criteria<br/>
- Do-not-intubate order<br/>
- Pneumonia caused by influenza<br/>
- Septic shock at baseline<br/>
- Other specified criteria<br/>
<br/>
Baseline Characteristics<br/>
- Gender distributions, pathogen profiles, and other baseline health characteristics were detailed.<br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
Patients randomized to hydrocortisone group received:<br/>
- 200mg intravenous hydrocortisone daily for 4 or 7 days based on clinical improvement, followed by tapering over a total of 8 or 14 days<br/>
- Standard therapy for severe community-acquired pneumonia (antibiotics and supportive care)<br/>
<br/>
Patients in placebo group received:<br/>
- Intravenous saline with an identical regimen to the hydrocortisone group<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
Primary Outcome:<br/>
- 28-day mortality rate (6.2% in the hydrocortisone group versus 11.9% in the placebo group, P=0.006)<br/>
<br/>
Secondary Outcomes:<br/>
- 90-day mortality rate<br/>
- Length of ICU stay<br/>
- Ventilator-free days and vasopressor-free days<br/>
- Incidence of endotracheal intubation in patients not ventilated at baseline<br/>
- Initiation of vasopressor therapy by day 28<br/>
- Changes in the Pao2:Fio2 ratio and SOFA score by day 7<br/>
- Quality of life assessed by SF-36 scores<br/>
<br/>
<h2><strong>Criticisms</strong></h2><br/>
- Lower than expected mortality in the control group suggests lower severity of illness than anticipated.<br/>
- No standardized microbiologic evaluation, with many patients with no documented pathogen.<br/>
- Exclusion of patients with septic shock.<br/>
- Did not evaluate the reversibility of glucocorticoid-induced hyperglycemia.<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
Funded by the French Ministry of Health.<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/>
Complete trial data and supplementary material are available at NEJM.org.
    <p></p>
</div>
</div>
</div>
</div>
</body>
</html>
